Market Cap : 1.27 B | Enterprise Value : 1.22 B | PE Ratio : At Loss | PB Ratio : |
---|
NYSE:MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Myovant Sciences's total current liabilities for the quarter that ended in Mar. 2022 was $250.3
The historical data trend for Myovant Sciences's Total Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.
Myovant Sciences's Total Current Liabilities for the fiscal year that ended in Mar. 2022 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 86.586 | + | 2.148 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 26.389 | + | 135.207 | |
= | 250.3 |
Myovant Sciences's Total Current Liabilities for the quarter that ended in Mar. 2022 is calculated as
Total Current Liabilities | = | Accounts Payable & Accrued Expense | + | Short-Term Debt & Capital Lease Obligation |
= | 86.586 | + | 2.148 | |
+ | Other Current Liabilities | + | Current Deferred Liabilities | |
= | 26.389 | + | 135.207 | |
= | 250.3 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
Stay away from companies that roll over the debt e.g. Bear Stearns
When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.
His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.
Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term
Thank you for viewing the detailed overview of Myovant Sciences's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Potter Myrtle S | director | 10 FINDERNE AVE BRIDGEWATER NJ 08807 |
Guinan Mark | director | C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094 |
Arjona Ferreira Juan Camilo | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Curran Terrie | director | C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Gulfo Adele M. | director | ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957 |
Sebelius Kathleen | director | C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025 |
Lang Matthew | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005 |
Sumitomo Chemical Co., Ltd. | 10 percent owner | 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 60 WALL STREET NEW YORK NY 10005 |
Seely Lynn | director, officer: Principal Executive Officer | 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107 |
Sablich Kim | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Nomura Hiroshi | director | C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005 |
Roivant Sciences Ltd. | 10 percent owner | CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 |
Torti Frank | director | 2855 SAND HILL ROAD MENLO PARK CA 94025 |
Other Sources
By Zacks 2021-05-10
By Zacks 2021-02-11
By Seekingalpha 2021-10-26
By Zacks 2021-05-11
By Seekingalpha 2020-12-22
By Seekingalpha 2021-05-24
By Fool 2021-07-28
By Seekingalpha 2022-01-26
By Zacks 2021-09-10
By Zacks 2021-04-13
By Zacks 2021-05-27
By Seekingalpha 2021-06-02
By Zacks 2020-12-29
By Seekingalpha 2021-07-28
By Fool 2020-12-28